X

Trial Profile

Randomized, three-period, crossover, single-dose trial of drug drug interactions between doravirine and ledipasvir/sofosbuvir

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doravirine (Primary) ; Ledipasvir/sofosbuvir (Primary)
Indications Hepatitis B; Hepatitis C; HIV-1 infections; Liver disorders
Focus Pharmacokinetics

Most Recent Events

27 Feb 2019 New trial record
19 Feb 2019 Results assessing drug-drug interactions (DDIs) between doravirine and two HCV treatments in two phase 1 drug interaction trials (MK-1439-053, MK-1439-050) published in the Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com